Holen Sie sich die Stockscreener-App
6.51
3.01%
0.19
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BHC?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$6.32
Offen:
$6.3
24-Stunden-Volumen:
1.12M
Relative Volume:
0.52
Marktkapitalisierung:
$2.41B
Einnahmen:
$9.47B
Nettoeinkommen (Verlust:
$-178.00M
KGV:
-13.56
EPS:
-0.48
Netto-Cashflow:
$1.01B
1W Leistung:
+1.40%
1M Leistung:
+5.34%
6M Leistung:
-15.67%
1J Leistung:
-14.00%
1-Tages-Spanne:
$6.29
$6.53
1-Wochen-Bereich:
$6.29
$6.53
52-Wochen-Spanne:
$3.96
$9.85
Bausch Health Companies Inc Stock (BHC) Company Profile
Firmenname
Bausch Health Companies Inc
Sektor
Telefon
514-744-6792
Adresse
2150 ST. ELZEAR BLVD. WEST, QUEBEC, QC
Vergleichen Sie BHC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BHC
Bausch Health Companies Inc
|
6.51 | 2.37B | 9.47B | -178.00M | 1.01B | -0.48 |
|
ZTS
Zoetis Inc
|
151.19 | 68.05B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.55 | 46.58B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.65 | 43.71B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.29 | 18.40B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
297.89 | 13.23B | 2.99B | 1.21B | 1.13B | 25.06 |
Bausch Health Companies Inc Stock (BHC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-02 | Herabstufung | Piper Sandler | Neutral → Underweight |
| 2024-07-10 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-09-20 | Hochstufung | Jefferies | Hold → Buy |
| 2023-06-16 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2022-07-29 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-07-29 | Herabstufung | Truist | Buy → Hold |
| 2022-07-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-06-13 | Fortgesetzt | JP Morgan | Overweight |
| 2021-03-24 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-02-17 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-01-22 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-09-17 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-08-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-17 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-24 | Eingeleitet | Citigroup | Buy |
| 2020-04-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-01-22 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2019-12-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-12-02 | Eingeleitet | Goldman | Neutral |
| 2019-10-25 | Eingeleitet | Cowen | Outperform |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-08-15 | Hochstufung | TD Securities | Hold → Buy |
| 2019-07-19 | Eingeleitet | Wolfe Research | Outperform |
| 2019-06-11 | Fortgesetzt | Barclays | Overweight |
| 2019-05-13 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2019-01-02 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-11-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-13 | Hochstufung | Piper Jaffray | Underweight → Neutral |
Alle ansehen
Bausch Health Companies Inc Aktie (BHC) Neueste Nachrichten
Bausch Health Companies Inc. Stock Analysis and ForecastExplosive market performance - Autocar Professional
IP Atty's FCA Suit Against Valeant Over Apriso Tossed Again - Law360
SANDRIDGE ENERGY, INC. ANNOUNCES APPOINTMENT OF BRETT ICAHN TO THE BOARD OF DIRECTORS - The Malaysian Reserve
Is Bausch Health Companies Inc. a good long term investmentDynamic capital growth - jammulinksnews.com
What analysts say about Bausch Health Companies Inc. stockTremendous return on equity - jammulinksnews.com
Brett Icahn Takes Board Seat at SandRidge Energy: Major Strategic Move for Oil Producer - Stock Titan
What drives Bausch Health Companies Inc. stock pricePhenomenal returns - Autocar Professional
Best Stock to Buy Right Now: Bausch Health vs Canopy Growth? - MSN
Bausch Health Faces Patent Drama And Policy Questions This Quarter - Finimize
Bausch Health's Xifaxan Patent Clarity, Policy Commentary in Focus for Q2, RBC Says - MarketScreener
In the Wake of Bausch Health Companies Inc.'s (NYSE:BHC) Latest US$196m Market Cap Drop, Institutional Owners May Be Forced to Take Severe Actions - 富途牛牛
In the wake of Bausch Health Companies Inc.'s (NYSE:BHC) latest US$196m market cap drop, institutional owners may be forced to take severe actions - simplywall.st
Amblyopia Market Growth Expected to See Next Level with Novartis - openPR.com
Bausch Health Companies (BHC) Canada Announces Expanded Availability of CABTREO Gel - Yahoo Finance
Icahn Enterprises shares rise 5.72% intraday after Bausch Health appoints new Chief Accounting Officer. - AInvest
Bausch Health's Strategic Leadership Shift: Steven Lee's Expertise Could Propel Valuation Growth Amid Transformation - AInvest
First-Ever Triple-Combination Acne Treatment CABTREO Expands Access Across Canadian Health Programs - Stock Titan
Bausch Health Names Steven Lee Chief Accounting Officer - MarketScreener
Bausch Health Appoints New Chief Accounting Officer - MarketScreener
Bausch Health Strengthens Finance Team: M&A Expert Steven Lee Takes Chief Accounting Officer Role - Stock Titan
Groundbreaking Triple-Combination Acne Treatment Expands Access Across Canadian Healthcare System - Stock Titan
Bausch Health's Gastroenterology Business, Salix Pharmaceuticals, Launches Fresh "I Wish I Knew" Campaign to Educate People About Xifaxan(R) (rifaximin) for Adults at Risk of Overt Hepatic Encephalopathy Recurrence - New Castle News
First FDA-Approved Drug Xifaxan Unveils Powerful Patient Stories in New Hepatic Encephalopathy Campaign - Stock Titan
SHAREHOLDER ALERT: Potential Recovery for Bausch Health Companies Inc. (BHC) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Bausch Health Companies Reaches Analyst Target Price - Nasdaq
August 22nd Options Now Available For Bausch Health Companies (BHC) - Nasdaq
Stocks In Play: Bausch Health Companies - Barchart.com
Bausch Health to Announce Second Quarter 2025 Results on July 30 - Corsicana Daily Sun
Bausch + Lomb's Dry Eye Campaign: A Strategic Opportunity in Growing Eye Health Markets - AInvest
BHC SEC FilingsBausch Health Companies Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Bausch + Lomb Brief: Closes Upsized 675 Million Euro Senior Secured Notes Offering and Partial Credit Agreement Refinancing - MarketScreener
Fed. Circ. Revives MSN Challenge To Bausch IBS Drug Patent - Law360
Bausch + Lomb Brief: Prices Upsized Senior Secured Notes Offering - MarketScreener
GMS Posts Upbeat Earnings, Joins Coinbase Global, Genworth Financial, Sandisk And Other Big Stocks Moving Higher On Wednesday - Benzinga
Bausch Health ticks higher following large director stock purchase - MSN
John Paulson buying at Bausch Health Companies (BHC) - The Globe and Mail
Bausch Health Companies: Insider Confidence Fuels Undervalued Stock's Turnaround Potential - AInvest
Bausch Health to Participate in the J.P. Morgan Global Leveraged Finance Conference - The Globe and Mail
Director buying at Bausch Health Companies (BHC) - The Globe and Mail
Bausch Health: Repricing Potential Driven By Deleveraging (NYSE:BHC) - Seeking Alpha
Finanzdaten der Bausch Health Companies Inc-Aktie (BHC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.09%
0.96%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):